- Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.
AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
4 reports, 3 independent
Updated Oct 30
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Investor concerns surface regarding the potential merger between AstraZeneca and Bristol-Myers Squibb.1 source
AstraZeneca sought a mega-merger with a US rival.1 source
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
Bristol-Myers Squibb
American pharmaceutical company